

FRONT

This document is approved by the Executive Directorate of Pharmacovigilance at SFDA

Entyvio[®]
vedolizumab

ENTYVIO (vedolizumab) Patient Alert Card

This alert card contains important safety information that you need to be aware of.

Show this card to any doctor involved in your treatment.



For extra copies please contact: +966 548038450

version number: 3.0
Date: Aug 2021

Inside left

Infections

- ENTYVIO increases the risk of getting infections.
- Infections may progress more rapidly and be more severe.
This may include serious brain and nervous system infections.
- You should not be treated with ENTYVIO if you have a severe infection.

If you develop symptoms suggestive of:

- **infections** for example fever, persistent cough, weight loss, listlessness, or;
- **nervous system problems** for example confusion, difficulties with vision or movement then you should seek medical attention immediately.

Inside right

Keep this card with you for 4 months after the last ENTYVIO dose, since side effects may occur a long time after your last dose of ENTYVIO.

- See the ENTYVIO package leaflet for more information.
- Please make sure you also have a list of all your other medicines with you at any visit to a health care professional.

- To report any side effect(s) please contact:

- Takeda Drug Safety Officer:
- E-mail: AE.SaudiArabia@takeda.com

Or The National Pharmacovigilance and Drug Safety Centre (NPC):

- Fax: +966-11-205-7662
- Phone: 19999
- E-mail: npc.drug@sfd.gov.sa
- Website: <http://ade.sfda.gov.sa/>

BACK

Patient's Name: _____

Doctor's Name: _____

Doctor's Phone: _____

Dates of ENTYVIO treatment:

Start: _____

Further Infusions: _____

- See the ENTYVIO package leaflet for more information.
- Please make sure you also have a list of all your other medicines with you at any visit to a health care professional.